Modern Approach to Metabolic Rehabilitation of Cancer Patients: Biguanides (Phenformin and Metformin) and Beyond

10.1016/S0140-6736(77)90442-1

Breslow L , AgranL, BreslowDM, MorgansternM, EllweinL: Cancer control: implications from its history.J. Natl Cancer Inst.59(2 Suppl.), 671–686 (1977).

Lowe J : The Metabolic Treatment of Fibromyalgia.McDowell Publishing, Lafayette, CO, USA, 312 (2000).

Dilman VM : Endocrinological Oncology. Meditsina Leningrad Russia (1983).

Dilman VM , BersteinLM, TsyrlinaEVet al.: On correction of hormonal-metabolic disturbances in oncological patients. Effect of biguanides (phenformin and adebit), misclerone and diphenin.Vopr. Onkol.21(11), 33–39 (1975).

Dilman VM , RyabovSI, TsyrlinaEVet al.: Reduction of body weight, cholesterol and glucose level under influence of metformin in patients with cancer and atherosclerosis.Vopr. Onkol.18(2), 84–86 (1972).

Dilman VM : Aging Climax and Cancer.Meditsina Leningrad Russia (1968).

10.1159/000225596

Dilman VM , BersteinLM, YevtushenkoTPet al.: Preliminary evidence on metabolic rehabilitation of cancer patients.Arch. Geschwulstf58, 175–183 (1988).

Dilman V , DeanW: The Neuroendocrine Theory of Aging and Degenerative Disease. The Center for Bio-Gerontology, Pensacola, FL, USA (1992).

Berstein LM , YevtushenkoTP, TsyrlinaEVet al.: Comparative study of 5- and 10-years results of metabolic rehabilitation of oncological patients. In: Neuroendocrine System, Metabolism, Immunity and Cancer. HansonKP, DilmanVM (Eds). NN Petrov Research Institute of Oncology Publ, St Petersburg, Russia, 102–112 (1992).

10.1007/978-0-387-78818-0

MacMahon B : Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist.Semin. Oncol.24(1 Suppl. 1), S1–S39 (1997).

Berstein LM : Oncoendocrinology: Traditions contemporary situation and perspectives. Nauka Publishers St Petersburg Russia (2004).

10.1097/CAD.0b013e3282f97f75

10.1016/j.jsbmb.2009.10.005

10.1002/cncr.22789

10.1016/0090-8258(85)90135-0

10.1093/humrep/dem088

10.4161/cbt.7.10.6663

10.1016/j.canlet.2004.11.011

10.1097/01.mol.0000191913.16321.60

10.1172/JCI13505

10.1586/era.09.71

10.1159/000195540

10.1016/j.jsbmb.2007.05.008

10.1038/nrc2713

10.1016/j.juro.2009.01.047

10.1016/j.ejca.2008.09.003

10.1016/j.ygyno.2006.09.019

Golubev AG : The other side of metabolism.Biokhimiia (Moscow)61(11), 2018–2039 (1996).

10.2174/138161208784139747

10.1158/1055-9965.EPI-09-0372

10.1126/science.123.3191.309

10.1016/j.ceb.2006.10.005

10.1016/j.cmet.2007.10.002

10.1016/j.tcb.2008.01.006

10.1038/nrc2676

10.1158/0008-5472.CAN-09-2994

10.1017/S1462399408000896

10.2217/14622416.8.8.917

10.1172/JCI32133

10.1007/978-0-387-78818-0_3

Bershtein LM , TsyrlinaEV, KovalevskiiAIet al.: Endocrine-genotoxic switchings as promoter of main noninfectious diseases.Vestn. Ross. Akad. Med. Nauk.1, 12–18 (2008) [in Russian].

10.2217/14796694.4.1.23

10.1007/978-0-387-78818-0_10

10.1158/1055-9965.EPI-08-0756

10.1038/nrc2536

10.1016/S1470-2045(09)70159-7

10.1210/jc.2005-1210

10.3816/CBC.2008.n.060

Demark-Wahnefried W , RockCL, PatrickK, ByersT: Lifestyle interventions to reduce cancer risk and improve outcomes.Am. Fam. Physician77(11), 1573–1578 (2008).

10.1007/978-1-60327-492-0_8

10.7326/0003-4819-152-1-201001050-00005

10.1016/j.maturitas.2010.01.004

10.1038/onc.2009.348

10.1111/j.1742-1241.2009.02025.x

10.1345/aph.1L181

10.4161/cc.8.6.7933

10.1016/j.exger.2005.07.007

10.1158/0008-5472.CAN-05-4061

10.1158/0008-5472.CAN-07-2310

10.1634/theoncologist.2009-0286

10.1042/BJ20080557

10.1016/j.ahj.2005.04.003

10.1016/j.ejca.2008.06.025

10.1007/s10549-009-0507-x

10.1016/j.bbrc.2008.09.111

10.1186/1741-7015-5-17

10.1002/mnfr.200700470

10.1111/j.1525-1438.2006.00297.x

10.1016/S0753-3322(05)80046-0

10.1172/JCI37398

10.1053/j.seminoncol.2009.10.011

10.1016/j.taap.2006.12.025

10.2174/092986708783885264

10.1111/j.1467-789X.2009.00592.x

10.1016/j.clnu.2009.02.006

10.1093/jnci/djj494

10.2217/fon.09.86

10.1053/j.gastro.2010.01.057

10.1586/egh.09.28

10.1016/j.cct.2009.05.001

10.1016/j.dsx.2007.11.002

10.1007/s10549-009-0507-x

10.2337/diacare.29.02.06.dc05-1558

10.1007/s00125-009-1440-6

10.2337/dc08-2175

10.1200/JCO.2009.24.5456

10.2217/fon.09.2

10.1007/s00432-004-0587-2

Ooi M KotoulaV CharalambousE: The antidiabetic biguanide metformin induces growth arrest in thyroid carcinoma cells in vitro .Presented at:Proc. 91th Annual Endocrine Soc. (USA)P2.521 (2009).

10.1016/j.ygyno.2009.09.024

Clinical trials.gov: metformin glitazones and cancer www.ClinicalTrials.gov (Accessed 21 January 2010)

Lloyd RS: DNA repair deficiency associated with obesity and the metabolic syndrome Report on NIH (USA) grant 1R01DK075974–01A2 2009–2014 www.researchprofiles.collexis.com/ohsuv3/grantDetail (Accessed 14 January 2010)